Hint mode is switched on Switch off
For swift navigation between sections

MaaT Pharma
LEI 969500CQQB6XUNW6CN97

Organization name
MaaT Pharma
Country name
France
Country of registration
France
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds
  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Quotes

Request sent
Access denied
Quotes provided by information providers are indicative in nature

Profile

MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors. The company has a portfolio of 2 products in clinical development, including 1 in Phase II (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase Ib (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).

Awards

Documentation

Stocks

Public debt by currencies

Codes

  • LEI
    969500CQQB6XUNW6CN97
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • SIREN
    808370100
Registration is required to get access.